Analysis Reports - TradeFomo

Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

All AAOI ACAD ADMA AGIO ALMS ALMU ALTS APGE AUPH AVAV BCRX CAI CAKE CEG CELC CEP CGON CIEN CNC COGT CRCL CTRI GCT GOOG GPCR HALO HIMS HOOD HWM IREN IVVD KALA KALV LENZ LEVI LITE LRMR LULU LUNR MDGL MESO MOH MTCH MU MVST NBIS NKE NRIX NVAX OKUR OLMA ONC OSCR PHAT PLRX PYG RBLX RDDT RIGL RKLB SGHC SPRY SRPT TARS TBPH TH TRVI TSHA UNH VEON VOR WVE XFOR ZLAB

Tarsus Pharmaceuticals (TARS) presents a strong "Buy" opportunity with a $72 price target. The company dominates the Demodex blepharitis market with its first-in-class therapy XDEMVY®, demonstrating exceptional commercial execution ($78.3M Q1 2025 revenue, +217% YoY).

Supported by a robust balance sheet ($408M cash) and broad payer coverage (>90%), Tarsus leverages its "platform-in-a-product" strategy centered on lotilaner. The synergistic pipeline, particularly TP-04 for Ocular Rosacea, offers significant expansion potential.

Tarsus Pharmaceuticals (NASDAQ: TARS) - Building a First-in-Class Ophthalmic Franchise

2025-07-31Change from report: +86.9%1M: +50.9%3M: +77.3%

Tarsus Pharmaceuticals (TARS) presents a strong "Buy" opportunity with a $72 price target. The company dominates the Demodex blepharitis market with its first-in-class therapy XDEMVY®, demonstrating exceptional commercial execution ($78.3M Q1 2025 revenue, +217% YoY). Supported by a robust balance sheet ($408M cash) and broad payer coverage (>90%), Tarsus leverages its "platform-in-a-product" strategy centered on lotilaner. The synergistic pipeline, particularly TP-04 for Ocular Rosacea, offers significant expansion potential.